Akademik Veri Yönetim Sistemi
6. BİLSEL INTERNATIONAL WORLD SCIENTIFIC AND RESEARCH CONGRESS, İstanbul, Türkiye, 28 - 29 Aralık 2024, ss.908-909, (Özet Bildiri)
Breast cancer is the most common malignant disease in women in Western countries, where the lifetime risk of developing cancer is >10% (1). The occurrence of synchronous bilateral breast cancer is very rare, accounting for only 1–3% of all breast cancer cases (2). Radiotherapy (RT) is an important part of the treatment for many breast cancer patients and has a definite role in reducing regional recurrences and improving recurrence-free survival. The application of RT in synchronous bilateral breast cancer is technically challenging due to its proximity to organs such as the heart, lungs, and esophagus. No standard RT technique has yet been proposed for synchronous bilateral breast cancer, and RT plans for synchronous bilateral breast cancer become more challenging when regional lymph node irradiation is needed. The aim of the present study was to evaluate the dosimetric and clinical outcomes of 10 patients who underwent bilateral RT for synchronous bilateral breast cancer/ductal carcinoma in situ between 2019 and 2024 in our clinic. The median age was 51 (29-80), four patients had a history of smoking, two patients had a family history of cancer, and one patient had a history of chronic disease. Three patients were premenopausal and seven patients were postmenopausal. Only one patient had DCIS in the right breast, and all other patients had invasive cancer. Nine patients were estrogen receptor positive, 8 patients were progesterone receptor positive, and 3 patients were HER2 positive. Two patients did not receive chemotherapy, 5 patients received neoadjuvant and 3 patients received adjuvant chemotherapy. The median RT dose for both breasts was 50 Gy. Doses to organs at risk are summarized in Table 1. Radiation dermatitis was seen in 70% and acute esophagitis in 30%, and no grade 3 or higher toxicity was observed. Median disease-free survival was 17 (2-90) months and median overall survival was 24 (10-96) months at a median follow-up of 25 months. Only two patients used the 3D conformal RT technique, and eight patients used IMRT and VMAT techniques. Although applying RT to two breasts at the same time is technically difficult, it has been observed that it does not cause serious toxicity with correct contouring and ideal patient-specific planning technique.